Trifluoroacetic acid → 8-Chloro-7-methyl-4-[3-(2-methyl-pyridin-4-yl)-phenyl]-1,3-dihydro-benzo[b][1,4]diazepin-2-one
반응식
C(OC(=O)[NH:7][C:8]1[CH:13]=[C:12]([Cl:14])[C:11]([CH3:15])=[CH:10][C:9]=1[NH:16][C:17](=O)[CH2:18][C:19]([C:21]1C=C[CH:24]=[C:23]([C:27]2[CH:32]=[CH:31][N:30]=[C:29]([CH3:33])[CH:28]=2)[CH:22]=1)=O)(C)(C)C.[C:36](O)([C:38](F)(F)F)=[O:37]>C(Cl)Cl>[Cl:14][C:12]1[C:11]([CH3:15])=[CH:10][C:9]2[N:16]=[C:17]([C:18]3[CH:19]=[CH:21][CH:22]=[C:23]([C:27]4[CH:32]=[CH:31][N:30]=[C:29]([CH3:33])[CH:28]=4)[CH:24]=3)[CH2:38][C:36](=[O:37])[NH:7][C:8]=2[CH:13]=1참가 물질
4
실험 절차
The title compound was prepared from (5-chloro-4-methyl-2-{3-[3-(2-methyl-pyridin-4-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester (Example M77) (0.36 g, 0.72 mmol) by treatment with TFA in CH2Cl2 according to the general procedure N. Obtained as a light yellow solid (220 mg, 81%).